Cardiac Dysfunction in Patients with Fatty Liver Disease

Launched by POST GRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH, CHANDIGARH · Apr 23, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating how non-alcoholic fatty liver disease (NAFLD) can affect heart function. Specifically, it looks at a condition called left ventricular diastolic dysfunction (LVDD), which means the heart has trouble relaxing properly between beats. This can lead to serious health issues, especially in people who are preparing for liver surgery or have other liver conditions. The study aims to understand the link between NAFLD and heart problems, particularly since many people with NAFLD also have other health issues like diabetes and high blood pressure.

To participate in this trial, individuals need to be between the ages of 18 and 65 and have a diagnosis of NAFLD confirmed through medical tests or imaging. Unfortunately, those who are older than 65 or have certain health conditions, like chronic kidney disease or serious heart problems, won’t be able to participate. If eligible, participants can expect to undergo evaluations that may include heart imaging tests and other assessments to help researchers better understand how NAFLD impacts heart health. This research is important as it could lead to better care and treatment options for people with both liver and heart conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age range of 18-65 years
• • metabolic dysfunction associated steatotic liver disease as diagnosed either by histology or clinical, laboratory, non invasive tests, USG findings and vibration controlled transient elastography (VCTE).
• Exclusion Criteria:
• • Age \>65 years
• • Chronic renal disease
• • Pregnancy and peripartum cardiomyopathy
• • Hypertension
• • Valvular heart disease
• • Sick sinus syndrome/ Pacemaker
• • Cardiac rhythm disorder
• • Hypothyroidism
• • Hyperthyroidism
• • Portal vein thrombosis
• • Transjugular intrahepatic porto systemic shunt (TIPS) insertion
• • Hepatocellular carcinoma
• • Anemia Hb \< 8gm/dl in females, and \< 9 gm/dl in males at the time of assessment